These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study. D'Erasmo L; Commodari D; Di Costanzo A; Minicocci I; Polito L; Ceci F; Montali A; Maranghi M; Arca M Nutr Metab Cardiovasc Dis; 2020 Oct; 30(11):2027-2035. PubMed ID: 32830020 [TBL] [Abstract][Full Text] [Related]
10. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors. Arca M Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383 [TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
12. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition? Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F; Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826 [TBL] [Abstract][Full Text] [Related]
13. Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle. Shek A; Alieva R; Kurbanov R; Hoshimov S; Nizamov U; Abdullaeva G; Nagay A Atherosclerosis; 2018 Oct; 277():524-529. PubMed ID: 30270094 [TBL] [Abstract][Full Text] [Related]
14. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study. Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335 [TBL] [Abstract][Full Text] [Related]
15. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study. Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240 [TBL] [Abstract][Full Text] [Related]
16. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL. Rallidis LS; Kiouri E; Katsimardos A; Kotakos C Atherosclerosis; 2018 Aug; 275():262-264. PubMed ID: 29980053 [TBL] [Abstract][Full Text] [Related]
17. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else? Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526 [TBL] [Abstract][Full Text] [Related]
18. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068 [TBL] [Abstract][Full Text] [Related]
19. LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis. Schreuder MM; Hamkour S; Siegers KE; Holven KB; Johansen AK; van de Ree MA; Imholz B; Boersma E; Louters L; Bogsrud MP; Retterstøl K; Visseren FLJ; Roeters van Lennep JE; Koopal C Atherosclerosis; 2023 Nov; 384():117117. PubMed ID: 37080805 [TBL] [Abstract][Full Text] [Related]
20. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience. Scicali R; Di Pino A; Urbano F; Ferrara V; Marchisello S; Di Mauro S; Scamporrino A; Filippello A; Rabuazzo AM; Purrello F; Piro S Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):869-879. PubMed ID: 33549441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]